The field of messenger RNA therapeutics is flying high as BioNTech and Pfizer conclude a phase III trial with their Covid-19 vaccine showing 95% effectiveness.
The phase III trial recruited over 43,000 volunteers to gauge whether Covid-19 infections could be prevented by a vaccine made out of messenger RNA (mRNA). One group received two doses of the candidate vaccine around three weeks apart, and another received a placebo.
According to topline phase III results, the placebo group had 162 confirmed cases of Covid-19 while the vaccine group had just eight. The effect was similar across different ages, genders, and ethnicities and no serious safety concerns were noted. Pfizer and BioNTech now aim to apply for an Emergency Use Authorization from the FDA, which allows the vaccine to be used before getting full approval.
BioNTech and Pfizer’s mRNA vaccine delivers the instructions for our body to produce Covid-19 antigens and thus train the immune system to recognize them and catch the virus.
As the first Covid-19 vaccine to complete a phase III trial, BioNTech and Pfizer’s mRNA candidate is one of the frontrunners in the Covid-19 vaccine race. However, competitors have upped the ante in the last week. Rival mRNA giant Moderna this week revealed almost 95% efficacy in phase III interim results,
The post mRNA Stocks Soar with Final Results of BioNTech’s Covid-19 Vaccine appeared first on Labiotech.eu.
Published on Thu, 19 Nov 2020 15:04:18 +0000 in support of power apps array contains value